Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,161.13
(
-0.06%
)
US TECH 100
26,503.60
(
-0.19%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
101.88
(
0.34%
)
Bitcoin
77,870.77
(
-1.00%
)
News Focus
News Focus
Post# of 257447
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122892
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 72255

Tuesday, 01/27/2009 7:39:58 AM

Tuesday, January 27, 2009 7:39:58 AM

Post# of 257447
Boston Globe columnist Steven Syre is a BIIB skeptic, evidently:

http://www.boston.com/business/articles/2009/01/27/banks_you_can_bank_on/

Any merger in the drug and biotech industries has one sure effect: Biogen Idec Inc. shares will jump. Sure enough, Pfizer Inc. agreed yesterday to buy Wyeth, and Biogen stock climbed $1.09, to $48.51. Biogen is routinely mentioned in speculation about drug industry mergers, though there's no evidence of any activity. The Cambridge company fought off the advances of activist investor Carl Icahn in a proxy fight last year.

LOL


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today